FDA Grants Priority Review To Sanofi Pasteur’s Application For Dengvaxia

STAT: FDA says it will consider approval of first dengue vaccine, despite controversy
“The Food and Drug Administration has agreed to consider Sanofi Pasteur’s application for Dengvaxia, the world’s first licensed vaccine that protects against dengue but one that brings with it considerable controversy and concern. The company announced Tuesday that it has received notice the regulatory agency will give the vaccine’s file a priority review, which means a decision must be rendered within six months…” (Branswell, 10/30).